Literature DB >> 2463174

Anticonvulsant profile of the dihydropyridine calcium channel antagonists, nitrendipine and nimodipine.

S J Dolin1, A B Hunter, M J Halsey, H J Little.   

Abstract

The effects of the dihydropyridine calcium channel antagonists, nitrendipine and nimodipine, on convulsions produced by different mechanisms have been studied in rats. Nitrendipine and nimodipine significantly raised the thresholds to pentylenetetrazol for up to six hours after their injection. The calcium channel agonist, BAY K 8644, lowered the convulsion threshold to pentylenetetrazol and antagonised the effects of nitrendipine. In contrast, the severity of seizures produced by N-methyl-dl-aspartate (NMA) was increased by nitrendipine. BAY K 8644 also slightly increased the effects of NMA. Nimodipine and nitrendipine caused small, but significant, increases in the threshold pressures for the convulsions caused by raising the atmospheric pressure with helium gas. The compounds had no effect on strychnine convulsions. The conclusion is that the calcium channel antagonists are anticonvulsant against only certain types of convulsions, such as pentylenetetrazol and high pressure (and ethanol withdrawal, reported previously). Others may be increased, such as NMA seizures, or unaffected, such as strychnine-induced convulsions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2463174     DOI: 10.1016/0014-2999(88)90831-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Psychopharmacological properties of calcium channel inhibitors.

Authors:  O Pucilowski
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Meta-analysis of initial seizure thresholds in electroconvulsive therapy.

Authors:  Jeroen A van Waarde; Bastiaan Verwey; Rose C van der Mast
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-04-21       Impact factor: 5.270

3.  Cromakalim (BRL 34915) counteracts the epileptiform activity elicited by diltiazem and verapamil in rats.

Authors:  P Popoli; A Pezzola; S Sagratella; Y C Zeng; A Scotti de Carolis
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

4.  Influence of nicardipine, nimodipine and flunarizine on the anticonvulsant efficacy of antiepileptics against pentylenetetrazol in mice.

Authors:  M Gasior; R Kamiński; T Brudniak; Z Kleinrok; S J Czuczwar
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Effects of dihydropyridine calcium channel antagonists in ethanol withdrawal; doses required, stereospecificity and actions of Bay K 8644.

Authors:  J M Littleton; H J Little; M A Whittington
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  The effects of Ca2+ antagonists and hydralazine on central 5-hydroxytryptamine biochemistry and function in rats and mice.

Authors:  A R Green; R J DeSouza; E M Davies; A J Cross
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

7.  Interactions between diltiazem and ethanol: differences from those seen with dihydropyridine calcium channel antagonists.

Authors:  W P Watson; H J Little
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

8.  Nitrendipine decreases benzodiazepine withdrawal seizures but not the development of benzodiazepine tolerance or withdrawal signs.

Authors:  S J Dolin; T L Patch; M Rabbani; R J Siarey; A R Bowhay; H J Little
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

9.  The differential effects of felodipine and nitrendipine on cerebral dihydropyridine binding ex vivo and the ethanol withdrawal syndrome in mice.

Authors:  W P Watson; A Misra; A J Cross; A R Green; H J Little
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

10.  Chronic dihydropyridine treatment can reverse the behavioural consequences of and prevent adaptations to, chronic ethanol treatment.

Authors:  M A Whittington; S J Dolin; T L Patch; R J Siarey; A R Butterworth; H J Little
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.